Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05020860
Title A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome in Patients With Early Stage Breast Cancer (RESPONSE)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Baylor Breast Care Center
Indications

estrogen-receptor positive breast cancer

Her2-receptor positive breast cancer

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Doxorubicin + Paclitaxel

Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel

Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.